Laser Efficiency on Metabolic Parameters

Effect of Non-invasive on Lipid Metabolism and Renal Out Comes in Metabolic Syndrome

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT06193746

Enrollment

Registered

2024-01-05

Start date

2023-04-10

Completion date

2023-10-10

Last updated

2024-01-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Metabolic Syndrome

Brief summary

Non-invasive laser therapy is laser blood irradiation improves many metabolic parameters. So, this study aims to assess the impact of Non-invasive laser therapy on lipid metabolism and renal out comes

Detailed description

The metabolic syndrome is a constellation of interrelated metabolic risk factors especially central obesity, dyslipidemia, hyperglycemia, which all affect worse their kidney function, and all of this causing mortality. This time line requires a quick procedure that will enable us to implement safe and non-invasive therapeutic instruments adjacent therapy for metabolic syndrome cases.

Interventions

DEVICEnon-invasive laser therapy

(diode laser, continuous output, in skin contact mode, 0.005W,0.2cm,beam spot area 0.03cm2, 288j/cm ,1800s) in the morning session, we measured lipid profile and kidney function before and after treatment to measure improvement

Study design

Observational model

COHORT

Time perspective

CROSS_SECTIONAL

Eligibility

Sex/Gender

ALL

Age

45 Years to 65 Years

Healthy volunteers

Yes

Inclusion criteria

* The patients have Metabolic syndrome, started more than one year ago. * BMI ranged 30- 35Kg/m2. * They are on medical therapy for more than one year. * Clinically stable.

Exclusion criteria

* taking specific drugs uncontrolled diseases * cardiovascular instability * sever e autonomic neuropathy * infection wound, * burn, allergy or another external injury * hypothyroidism * hemorrhagic disorders * history of cancer * pregnant women, * mental illness as schizophrenia or dementia.

Design outcomes

Primary

Measure	Time frame	Description
lipid profile change	12 weeks following end of treatment	laboratorial measurement of lipid in one mg/dl of blood
glomerular function range change	12 weeks following end of treatment	laboratorial measurement of glomerular function range in one ml of blood/1minute/1.73m2
creatinine change	12 weeks following end of treatment	laboratorial measurement of creatinine one mg/DL of blood

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026